EDN1 and neoplasm: Studies have proven that the inhibition of the mutated Epidermal Growth Factor (EGF) promotes the release of endothelin-1 (EDN1), which strengthens as cells that make up the mass of the tumor lose the epithelial phenotype in exchange for a mesenchymal one (epithelial–mesenchymal transition), which is a key factor determining metastasis [34].